Kidney transplant patients may swap monthly IV for weekly shots in new study
NCT ID NCT04955366
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether kidney transplant patients can safely switch from monthly belatacept IV infusions to weekly abatacept injections without losing kidney function. The study enrolls 87 low-risk adults who are at least two years post-transplant. Researchers will compare kidney function between the two groups over 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Abatacept (Orencia) and belatacept (Nulojix), both immunosuppressive drugs
- What this could lead to
- If successful, this could offer kidney transplant patients a more convenient at-home injection option instead of monthly IV infusions, while maintaining kidney function.
- What could go wrong
- This is a small, early-phase (2b) study at a single center, so results may not apply broadly. Switching drugs could still lead to kidney function decline or rejection, and both drugs suppress the immune system, raising infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL TRANSPLANT RECIPIENT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital (EUH)
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.